Most regulated companies celebrate a successful AI pilot. They shouldn't. The pilot is where AI goes to die quietly — and the medical device industry is proof.
Every regulated company I talk to has the same story. They ran a pilot. It went well. Leadership was impressed. Someone got promoted.
And then nothing happened.
Eighteen months later, that pilot is still running on the same three users, with the same narrow dataset, inside the same sandboxed environment that compliance signed off on. Meanwhile, everyone's waiting for someone else to figure out what full deployment actually means.
This is the pilot trap. And in medical device, it's particularly brutal.
Medical device companies don't fail at AI because they lack ambition. They fail because scaling AI requires them to solve three problems simultaneously: regulatory validation, operational change management, and technical infrastructure — and most organizations are only set up to solve one of those at a time.
A pilot sidesteps all three. You can run a proof-of-concept with a limited user group, a narrow use case, and a quiet gentleman's agreement with your QA team that this doesn't trigger a full 21 CFR Part 11 review. That's fine. That's the point of a pilot.
But the moment you say let's scale this, every one of those deferred decisions comes due. All at once.
Your validation documentation doesn't cover the expanded workflow. Your change control board hasn't seen anything this broad in years. Your compliance team, who already has 40 open CAPAs, now has to figure out whether your AI model constitutes a Software as a Medical Device under current FDA guidance. And your IT team is still trying to figure out how the pilot even ran without a formal integration.
The result: paralysis dressed up as process.
Here's the thing most AI vendors won't tell you: the technology is the easy part. The hard part is what happens when the AI workflow touches a regulated process and nobody's written the SOP yet.
In a mid-market medical device company — say, 500 to 5,000 employees — you typically don't have a dedicated AI governance team. You have a quality director who's already stretched, an IT manager who's skeptical, and a VP of Operations who championed the pilot and is now quietly hoping someone else drives the next step.
Scaling AI in that environment requires a fundamentally different approach than what most consultants and vendors pitch. You can't treat it like an enterprise software rollout. And you can't treat it like a research project.
You have to treat it like a regulated process change — which means validation first, integration second, and training last. Not the other way around.
The framing gaining traction in healthcare is treating enterprise AI not as a collection of point solutions, but as a platform capable of running and governing multiple models across multiple workflows. That's a useful mental model. But it glosses over the operational reality for most mid-market companies.
For a company your size, platform thinking doesn't mean buying an AI platform. It means making four decisions once, so you don't have to remake them every time you want to extend AI to a new workflow.
1. Governance structure. Who owns AI decisions? Not who runs the tools — who owns the accountability when an AI output affects a regulated output? Define this before your second deployment, not after your fifth.
2. Validation approach. Establish a repeatable validation template now — one that your QA team has signed off on and can apply to new models with minimal rework. The goal is to compress the compliance review cycle, not eliminate it.
3. Change control integration. AI deployments should flow through your existing change control process. If they don't, you'll be building parallel governance infrastructure forever. Get your CCB familiar with AI change packages now.
4. Data provenance standards. Know where every input to every AI model comes from, and document it. Auditors will ask. Your future self will thank you.
None of this is glamorous. It's the unsexy infrastructure work that pilots never require — and that scaling always does.
A successful pilot is not a mandate to scale. It's a proof that the technology works under controlled conditions. Before you push the button on broader deployment, ask your team one honest question: have we solved the compliance, change control, and data governance problems that the pilot never had to face?
If the answer is no — or even mostly — you're not ready to scale. You're ready to plan the work that makes scaling possible.
That's not a delay. That's the job.
Dealing with a similar challenge?
We work with mid-market companies in regulated industries to build AI workflows that actually hold up.
Let's TalkSean Cummings
Founder of Laminar Flow Analytics. Specializes in AI workflow automation for regulated industries — medical device, financial services, and complex logistics operations.